Sitagliptin
Sitagliptin TZF contains the active substance sitagliptin, which belongs to a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors), which reduce blood sugar levels in adults with type 2 diabetes.
This medicine helps to increase the amount of insulin released after a meal and decrease the amount of sugar produced by the body.
Your doctor has prescribed this medicine to reduce high blood sugar levels caused by type 2 diabetes. This medicine can be used alone or in combination with other medicines that reduce blood sugar levels (insulin, metformin, sulfonylureas, or glitazones), which you may already be taking for your diabetes, along with diet and exercise.
What is type 2 diabetes?
Type 2 diabetes is a condition where the body does not produce enough insulin, and the insulin produced does not work as it should. The body may also produce too much sugar.
If this happens, sugar (glucose) builds up in the blood. This can lead to serious health problems, such as heart disease, kidney disease, loss of vision, and limb amputation.
There have been reports of pancreatitis (inflammation of the pancreas) in patients taking sitagliptin (see section 4).
If you experience blisters on your skin, this may be a sign of a condition called bullous pemphigoid. Your doctor may advise you to stop taking sitagliptin.
Because this medicine only works when your blood sugar levels are high, it is unlikely to cause low blood sugar levels (hypoglycemia). However, when taken with a sulfonylurea or insulin, it may cause low blood sugar levels. Your doctor may reduce the dose of the sulfonylurea or insulin.
Children and adolescents under 18 years of age should not take this medicine. This medicine is not effective in children and adolescents aged 10 to 17 years. It is not known if this medicine is safe and effective in children under 10 years of age.
Tell your doctor or pharmacist about all the medicines you are taking, have recently taken, or might take.
In particular, tell your doctor if you are taking digoxin (a medicine used to treat heart rhythm disorders and other heart conditions). When taking Sitagliptin TZF with digoxin, your doctor may need to check your digoxin blood levels.
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Do not take this medicine if you are pregnant.
It is not known if this medicine passes into breast milk. Do not take this medicine while breastfeeding or if you are planning to breastfeed.
This medicine has no or negligible influence on the ability to drive and use machines. However, dizziness and drowsiness have been reported, which may affect your ability to drive or use machines.
Taking this medicine with sulfonylureas or insulin may cause low blood sugar levels (hypoglycemia), which may affect your ability to drive or use machines or work without safe support for your feet.
Sitagliptin TZF contains less than 1 mmol (23 mg) of sodium per film-coated tablet, which is essentially sodium-free.
Always take this medicine exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.
The usual recommended dose is:
If you have kidney problems, your doctor may prescribe a lower dose of Sitagliptin TZF (such as 25 mg or 50 mg).
This medicine can be taken with or without food and drink.
Your doctor may prescribe this medicine alone or in combination with other medicines that reduce blood sugar levels.
Diet and exercise help your body use sugar from your blood. While taking Sitagliptin TZF, it is important to follow the diet and exercise plan recommended by your doctor.
If you take more than you should, contact your doctor immediately.
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose.
To maintain control of your blood sugar levels, you should continue to take this medicine as long as your doctor recommends.
Do not stop taking this medicine without first talking to your doctor.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
STOP taking Sitagliptin TZF and contact your doctor immediatelyif you experience any of the following serious side effects:
If you experience a severe allergic reaction (frequency not known), including rash, hives, blisters on the skin, or peeling of the skin, and swelling of the face, lips, tongue, and throat, which may cause difficulty breathing or swallowing, stop taking this medicine and contact your doctor immediately. Your doctor may prescribe a medicine to treat the allergic reaction and another medicine to treat your diabetes.
The following side effects have been reported:
Common(may affect up to 1 in 10 people): low blood sugar levels, nausea, bloating, vomiting
Uncommon(may affect up to 1 in 100 people): stomach pain, diarrhea, constipation, drowsiness
Some patients have reported various gastrointestinal symptoms after starting sitagliptin in combination with metformin (common).
Very common(may affect more than 1 in 10 people): low blood sugar levels
Common: constipation
Common: bloating, swelling of the hands or feet
Common: swelling of the hands or feet
Common: flu
Uncommon: dry mouth
Common: low blood sugar levels, headache, upper respiratory tract infections, stuffy or runny nose, and sore throat, osteoarthritis, pain in the arm or leg
Uncommon: dizziness, constipation, itching
Rare(may affect up to 1 in 1,000 people): reduced platelet count
Frequency not known(cannot be estimated from the available data): kidney problems (sometimes requiring dialysis), vomiting, joint pain, muscle pain, back pain, interstitial lung disease, bullous pemphigoid (a type of blistering skin condition).
If you experience any side effects, including any not listed in this leaflet, tell your doctor or pharmacist.
Side effects can be reported directly to the Department of Drug Safety, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Aleje Jerozolimskie 181C; 02-222 Warsaw
phone: +48 22 49 21 301
fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the blister and carton after "EXP". The expiry date refers to the last day of that month.
Batch number means batch number.
There are no special storage instructions for this medicine.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
The active substance is sitagliptin.
Sitagliptin TZF, 25 mg
Each film-coated tablet contains 25 mg of sitagliptin as sitagliptin phosphate monohydrate.
Sitagliptin TZF, 50 mg
Each film-coated tablet contains 50 mg of sitagliptin as sitagliptin phosphate monohydrate.
Sitagliptin TZF, 100 mg
Each film-coated tablet contains 100 mg of sitagliptin as sitagliptin phosphate monohydrate.
The other ingredients are: calcium hydrogen phosphate, microcrystalline cellulose type 102, sodium carmellose, colloidal anhydrous silica, sodium stearyl fumarate, magnesium stearate
Coating: polyvinyl alcohol, titanium dioxide (E 171), macrogol 3350, talc, yellow iron oxide (E 172), red iron oxide (E 172).
The 25 mg film-coated tablets do not contain yellow iron oxide (E 172) and contain black iron oxide (E 172) instead.
Sitagliptin TZF, 25 mg
Round, pink film-coated tablet. Dimensions: 6.3 mm ± 0.5 mm in diameter.
Sitagliptin TZF, 50 mg
Round, light beige film-coated tablet with "S" engraved on one side.
Dimensions: 8.0 mm ± 0.5 mm in diameter.
Sitagliptin TZF, 100 mg
Round, beige film-coated tablet. Dimensions: 10.0 mm ± 0.5 mm in diameter.
PVC/PE/PVDC/Aluminum blister pack.
28 film-coated tablets packed with a leaflet in a cardboard box.
Marketing Authorization Holder
Tarchomińskie Zakłady Farmaceutyczne "Polfa" S.A.
ul. A. Fleminga 2
03-176 Warsaw
Phone number: 22 811-18-14
For more information about this medicine, contact the marketing authorization holder.
Manufacturer
Galenicum Health S.L.
Calle De San Gabriel 50
08950 Esplugues de Llobregat
Spain
SAG Manufacturing S.L.
Carretera Nacional 1 Km 36
28750 San Augustin del Guadalix
Spain
Tarchomińskie Zakłady Farmaceutyczne "Polfa" S.A.
ul. A. Fleminga 2
03-176 Warsaw
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.